← Back
$DYN All transactions

Dyne Therapeutics, Inc.

▼ SELL 10b5-1 Plan

$ Value

$2K

Shares

148

Price

$15

Filed

Mar 6

Insider

Name

Friedl-Naderer Johanna

Title

Chief Commercial Officer

CIK

0001915598

Roles

Officer

Transaction Details

Transaction Date

2026-03-05

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

154,581

Footnotes

Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. | Includes 129,790 unvested RSUs.

Filing Info

Accession No.

0001193125-26-096523

Form Type

4

Issuer CIK

0001818794

Friedl-Naderer Johanna's History

Date Ticker Type Value
2026-03-05 DYN $2K
2026-02-12 DYN A $0
2026-02-12 DYN A $0
2025-12-05 DYN $3K
2025-09-05 DYN $2K
2025-09-04 DYN $12K
2025-07-16 DYN A $0
2025-06-05 DYN $2K

Other Insiders at DYN (90d)

Insider Bought Sold Last
Posner Brian S $118K 2026-03-30
Cox John
CEO & President
$41K 2026-03-05
Rhodes Jason P $16.5M 2026-04-22
Lucera Erick
Chief Financial Officer
$107K 2026-04-01
Kerr Douglas
Chief Medical Officer
$13K 2026-03-05
Kersten Dirk $24.7M 2026-04-22
Friedl-Naderer Johanna
Chief Commercial Officer
2026-02-12